



15 February 2022

Novartis Pharma AG  
Basel, Switzerland  
CH-4002

Reference: EudraCT 2020-002288-69 Novartis Protocol ID CINC280A2203.

A Phase II, Open-Label, Multicenter Study of Capmatinib in Participants with MET exon 14 skipping mutation positive, advanced, Non Small-Cell Lung Cancer that has metastasized to the Brain

Trial 2020-002288-69 was cancelled with no patient enrollment and as such, no results will be reported.